Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51.

@article{Yao2007SynergismBE,
  title={Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51.},
  author={Qing Yao and Brenda Weigel and John H. Kersey},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2007},
  volume={13 5},
  pages={1591-600}
}
PURPOSE DNA-damaging agents, such as etoposide, while clinically useful in leukemia therapy, are limited by DNA repair pathways that are not well understood. 17-(Allylamino)-17-demethoxygeldanamycin (17-AAG), an inhibitor of the molecular chaperone heat shock protein 90 (Hsp90), inhibits growth and induces apoptosis in FLT3(+) leukemia cells. In this study, we evaluated the effects of etoposide and 17-AAG in leukemia cells and the roles of Hsp90, FMS-like tyrosine kinase 3 (FLT3), checkpoint… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Hsp90: A New Player in DNA Repair?

Biomolecules • 2015
View 9 Excerpts
Highly Influenced

Receptor Tyrosine Kinases: Family and Subfamilies

Wheeler Yosef Yarden
Springer International Publishing • 2015

References

Publications referenced by this paper.
Showing 1-10 of 47 references

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2005

Similar Papers

Loading similar papers…